Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Divis Laboratories Ltd
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,951 | 1,778 | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 |
| Expenses + | 1,464 | 1,274 | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 |
| Operating Profit | 487 | 504 | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 |
| OPM % | 25% | 28% | 25% | 26% | 32% | 29% | 31% | 32% | 34% | 30% | 33% | 34% | 33% |
| Other Income + | 66 | 81 | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 14 | 155 |
| Interest | 0 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 |
| Depreciation | 87 | 93 | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 |
| Profit before tax | 466 | 492 | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 |
| Tax % | 31% | 28% | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% |
| Net Profit + | 321 | 356 | 348 | 358 | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 |
| EPS in Rs | 12.09 | 13.41 | 13.11 | 13.49 | 20.27 | 16.20 | 19.21 | 22.19 | 24.94 | 20.53 | 25.95 | 21.96 | 28.29 |
Financials of Divis Laboratories Ltd
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,115 | 3,776 | 4,064 | 3,891 | 4,946 | 5,394 | 6,969 | 8,960 | 7,768 | 7,845 | 9,360 | 10,560 |
| Expenses + | 1,942 | 2,354 | 2,615 | 2,622 | 3,072 | 3,568 | 4,102 | 5,075 | 5,397 | 5,635 | 6,387 | 7,119 |
| Operating Profit | 1,173 | 1,423 | 1,450 | 1,269 | 1,874 | 1,826 | 2,867 | 3,885 | 2,370 | 2,210 | 2,973 | 3,441 |
| OPM % | 38% | 38% | 36% | 33% | 38% | 34% | 41% | 43% | 31% | 28% | 32% | 33% |
| Other Income + | 38 | 93 | 72 | 107 | 154 | 186 | 57 | 112 | 344 | 335 | 348 | 433 |
| Interest | 3 | 5 | 3 | 2 | 5 | 7 | 2 | 2 | 2 | 4 | 3 | 23 |
| Depreciation | 136 | 118 | 123 | 142 | 169 | 186 | 256 | 312 | 343 | 378 | 402 | 463 |
| Profit before tax | 1,072 | 1,393 | 1,395 | 1,231 | 1,855 | 1,819 | 2,666 | 3,684 | 2,369 | 2,163 | 2,916 | 3,388 |
| Tax % | 21% | 19% | 24% | 29% | 27% | 24% | 26% | 20% | 23% | 26% | 25% | 24% |
| Net Profit + | 852 | 1,126 | 1,060 | 877 | 1,353 | 1,377 | 1,984 | 2,960 | 1,823 | 1,600 | 2,191 | 2,568 |
| EPS in Rs | 32.07 | 42.41 | 39.95 | 33.04 | 50.96 | 51.85 | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 | 96.73 |
| Dividend Payout % | 31% | 24% | 25% | 30% | 31% | 31% | 27% | 27% | 44% | 50% | 36% | 31% |
Financials of Divis Laboratories Ltd
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 3,469 | 4,240 | 5,304 | 5,872 | 6,904 | 7,257 | 9,242 | 11,675 | 12,714 | 13,518 | 14,916 | 16,708 |
| Borrowings + | 27 | 42 | 36 | 63 | 106 | 39 | 5 | 4 | 3 | 3 | 4 | 7 |
| Other Liabilities + | 883 | 562 | 762 | 797 | 973 | 1,183 | 1,471 | 1,628 | 1,654 | 1,886 | 1,948 | 3,265 |
| Total Liabilities | 4,405 | 4,898 | 6,155 | 6,785 | 8,036 | 8,531 | 10,771 | 13,360 | 14,425 | 15,460 | 16,921 | 20,033 |
| Fixed Assets + | 1,309 | 1,439 | 1,559 | 1,996 | 2,088 | 2,782 | 3,704 | 4,325 | 4,723 | 4,739 | 5,442 | 6,528 |
| CWIP | 218 | 264 | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 778 | 1,022 | 2,113 |
| Investments | 733 | 803 | 1,631 | 1,889 | 1,946 | 971 | 0 | 72 | 77 | 82 | 65 | 69 |
| Other Assets + | 2,145 | 2,392 | 2,521 | 2,780 | 3,511 | 3,858 | 6,356 | 8,493 | 9,413 | 9,861 | 10,392 | 11,323 |
| Total Assets | 4,405 | 4,898 | 6,155 | 6,785 | 8,036 | 8,531 | 10,771 | 13,360 | 14,425 | 15,460 | 16,921 | 20,033 |
Financials of Divis Laboratories Ltd
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 826 | 1,038 | 1,150 | 776 | 954 | 1,216 | 1,947 | 1,912 | 2,460 | 1,261 | 1,653 | 2,738 |
| Cash from Investing Activity + | -521 | -406 | -1,140 | -478 | -685 | -83 | 75 | -2,195 | -2,708 | -269 | -804 | -2,219 |
| Cash from Financing Activity + | -303 | -631 | 2 | -314 | -246 | -1,091 | -35 | -532 | -797 | -799 | -799 | -804 |
| Net Cash Flow | 3 | 0 | 13 | -17 | 23 | 41 | 1,987 | -816 | -1,045 | 193 | 50 | -285 |
| Free Cash Flow | 519 | 642 | 774 | 502 | 221 | 33 | 1,037 | 1,199 | 1,987 | 258 | 215 | 221 |
| CFO/OP | 88% | 91% | 100% | 82% | 77% | 91% | 90% | 66% | 124% | 74% | 83% | 105% |
Financials of Divis Laboratories Ltd
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 85 | 81 | 95 | 86 | 96 | 88 | 99 | 84 | 100 | 106 | 103 |
| Inventory Days | 350 | 293 | 307 | 314 | 347 | 316 | 329 | 341 | 352 | 364 | 311 | 353 |
| Days Payable | 68 | 56 | 104 | 96 | 96 | 100 | 117 | 96 | 89 | 94 | 88 | 108 |
| Cash Conversion Cycle | 368 | 322 | 284 | 313 | 336 | 312 | 300 | 344 | 347 | 370 | 330 | 348 |
| Working Capital Days | 140 | 158 | 147 | 176 | 169 | 180 | 152 | 177 | 188 | 206 | 192 | 195 |
| ROCE % | 33% | 36% | 29% | 22% | 29% | 25% | 32% | 35% | 19% | 16% | 20% | 22% |